Nilotinib Teva (Nilotinib)

Nilotinib binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, preventing phosphorylation of downstream substrates. This blocks signaling pathways that promote leukemic cell proliferation and survival. The drug also inhibits related kinases such as PDGFR and c‑KIT, adding to its antitumor activity.

The specific dose of Nilotinib Teva is determined by the prescribing physician based on the patient’s disease stage, prior therapy, and individual health factors. Dosing regimens are individualized and should follow the prescriber’s written instructions and local regulatory guidelines.

Safety data for nilotinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency and selectivity than first‑generation agents such as imatinib. Compared with other second‑generation drugs like dasatinib, nilotinib has a distinct safety profile, notably a higher risk of QT prolongation but lower incidence of pleural effusion.

Nilotinib Teva should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to extreme temperatures or humidity to maintain its stability.

Nilotinib Teva is taken orally, usually as tablets, with a full glass of water. It is typically administered twice daily on an empty stomach, at least one hour before or two hours after a meal, to ensure optimal absorption. Patients should follow the prescriber’s exact instructions.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatic injury, pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of cardiac, liver and pancreatic function is essential to detect these events early.

Patients with a known hypersensitivity to nilotinib or any of its excipients should avoid the drug. Those with uncontrolled cardiac arrhythmias, significant QT prolongation, severe hepatic impairment, or who are taking contraindicated strong CYP3A4 inhibitors should not be treated with nilotinib without careful risk assessment.